<table id="t9" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 9: Drugs That are Affected by and Affecting Ciprofloxacin
</caption>
<col align="left" width="23.967%"></col>
<col align="left" width="28.667%"></col>
<col align="left" width="47.367%"></col>
<tbody>
<tr>
<td align="left" colspan="3" stylecode="Toprule Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Drugs That are Affected by Ciprofloxacin</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Drug(s)</content>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Recommendation</content>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<content stylecode="bold">Comments</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Tizanidine
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Contraindicated
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Concomitant administration of tizanidine and Ciprofloxacin is contraindicated due to the potentiation of hypotensive and sedative effects of tizanidine [
          
    
     
          
    
     <content stylecode="italics">see Contraindications (
           
     
      
           
     
      <linkhtml href="#s35">4.2</linkhtml>)
          
    
     
          
    
     </content>]

         
   
    
         
   
    </td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Theophylline
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Avoid Use (Plasma Exposure Likely to be Increased and Prolonged)
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Concurrent administration of Ciprofloxacin with theophylline may result in increased risk of a patient developing central nervous system (CNS) or other adverse reactions. If concomitant use cannot be avoided, monitor serum levels of theophylline and adjust dosage as appropriate. 
          
    
     
          
    
     <content stylecode="italics">[See Warnings and Precautions (
           
     
      
           
     
      <linkhtml href="#s42">5.6</linkhtml>).]
          
    
     
          
    
     </content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Drugs Known to Prolong QT Interval
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Avoid Use
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Ciprofloxacin may further prolong the QT interval in patients receiving drugs known to prolong the QT interval (for example, class IA or III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) 
          
    
     
          
    
     <content stylecode="italics">[see Warnings and Precautions (
           
     
      
           
     
      <linkhtml href="#s46">5.10</linkhtml>) and Use in Specific Populations (
           
     
      
           
     
      <linkhtml href="#s68">8.5</linkhtml>)].
          
    
     
          
    
     </content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Oral antidiabetic drugs
          
    
     
          
    
     <br/>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Use with caution Glucose-lowering effect potentiated
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Hypoglycemia sometimes severe has been reported when Ciprofloxacin and oral antidiabetic agents, mainly sulfonylureas (for example, glyburide, glimepiride), were co-administered, presumably by intensifying the action of the oral antidiabetic agent. Fatalities have been reported. Monitor blood glucose when Ciprofloxacin is co-administered with oral antidiabetic drugs. 
          
    
     
          
    
     <content stylecode="italics">[See Adverse Reactions (
           
     
      
           
     
      <linkhtml href="#s54">6.1</linkhtml>).]
          
    
     
          
    
     </content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Phenytoin
          
    
     
          
    
     <br/>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Use with caution Altered serum levels of phenytoin (increased and decreased)
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">To avoid the loss of seizure control associated with decreased phenytoin levels and to prevent phenytoin overdose-related adverse reactions upon Ciprofloxacin discontinuation in patients receiving both agents, monitor phenytoin therapy, including phenytoin serum concentration during and shortly after co-administration of Ciprofloxacin with phenytoin.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Cyclosporine
          
    
     
          
    
     <br/>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Use with caution (transient elevations in serum creatinine)
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor renal function (in particular serum creatinine) when Ciprofloxacin is co-administered with cyclosporine.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Anti-coagulant drugs
          
    
     
          
    
     <br/>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Use with caution (Increase in anticoagulant effect)
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">The risk may vary with the underlying infection, age and general status of the patient so that the contribution of Ciprofloxacin to the increase in INR (international normalized ratio) is difficult to assess. Monitor prothrombin time and INR frequently during and shortly after co-administration of Ciprofloxacin with an oral anti-coagulant (for example, warfarin).
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Methotrexate
          
    
     
          
    
     <br/>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Use with caution Inhibition of methotrexate renal tubular transport potentially leading to increased methotrexate plasma levels
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Potential increase in the risk of methotrexate associated toxic reactions. Therefore, carefully monitor patients under methotrexate therapy when concomitant Ciprofloxacin therapy is indicated.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Ropinirole
          
    
     
          
    
     <br/>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Use with caution
          
    
     
          
    
     <br/>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitoring for ropinirole-related adverse reactions and appropriate dose adjustment of ropinirole is recommended during and shortly after coadministration with Ciprofloxacin 
          
    
     
          
    
     <content stylecode="italics">[see Warnings and Precautions (
           
     
      
           
     
      <linkhtml href="#s51">5.15</linkhtml>)].
          
    
     
          
    
     </content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Clozapine
          
    
     
          
    
     <br/>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Use with caution
          
    
     
          
    
     <br/>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Careful monitoring of clozapine associated adverse reactions and appropriate adjustment of clozapine dosage during and shortly after co-administration with Ciprofloxacin are advised.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">NSAIDs
          
    
     
          
    
     <br/>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Use with caution
          
    
     
          
    
     <br/>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Non-steroidal anti-inflammatory drugs (but not acetyl salicylic acid) in combination of very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies and in postmarketing.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Sildenafil
          
    
     
          
    
     <br/>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Use with caution Two-fold increase in exposure
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Monitor for sildenafil toxicity (
          
    
     
          
    
     <content stylecode="italics">see Pharmacokinetics 
           
     
      
           
     
      <linkhtml href="#s75">12.3</linkhtml>
</content>).

         
   
    
         
   
    </td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Duloxetine
          
    
     
          
    
     <br/>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Avoid Use
          
    
     
          
    
     <br/>Five-fold increase in duloxetine exposure

         
   
    
         
   
    </td>
<td align="left" stylecode="Botrule Rrule" valign="top">If unavoidable, monitor for duloxetine toxicity.
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Caffeine/Xanthine
          
    
     
          
    
     <br/>Derivatives
          
    
     
          
    
     <br/>
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Use with caution
          
    
     
          
    
     <br/>Reduced clearance resulting in elevated levels and prolongation of serum half-life

         
   
    
         
   
    </td>
<td align="left" stylecode="Botrule Rrule" valign="top">Ciprofloxacin inhibits the formation of paraxanthine after caffeine administration (or pentoxifylline containing products). Monitor for xanthine toxicity and adjust dose as necessary.
</td>
</tr>
<tr>
<td align="center" colspan="3" stylecode="Botrule Lrule Rrule" valign="top">
<content stylecode="bold">Drug(s) Affecting Pharmacokinetics of Ciprofloxacin</content>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Antacids, Sucralfate, Multivitamins and Other Products Containing Multivalent Cations (magnesium/aluminum antacids; polymeric phosphate binders (for example, sevelamer, lanthanum carbonate); sucralfate; VidexÂ®
          
    
     
          
    
     <br/>(didanosine) chewable/buffered tablets or pediatric powder; other highly buffered drugs; or products containing calcium, iron, or zinc and dairy products)

         
   
    
         
   
    </td>
<td align="center" stylecode="Botrule Rrule" valign="top">Ciprofloxacin should be taken at least two hours before or six hours after Multivalent cation-containing products administration 
          
    
     
          
    
     <content stylecode="italics">[see Dosage and Administration. (
           
     
      
           
     
      <linkhtml href="#s22">2</linkhtml>)].
          
    
     
          
    
     </content>
<br/>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Decrease Ciprofloxacin absorption, resulting in lower serum and urine levels
          
    
     
          
    
     <br/>
</td>
</tr>
<tr>
<td align="left" stylecode="Botrule Lrule Rrule" valign="top">Probenecid
</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Use with caution (interferes with renal tubular secretion of Ciprofloxacin and increases Ciprofloxacin serum levels)
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Potentiation of Ciprofloxacin toxicity may occur.
</td>
</tr>
</tbody>
</table>